Contact Us
Drug Search Results
More Filters [+]

Eptotermin alfa

Alternative Names: eptotermin alfa, bmp-7, bmp 7, bmp7
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TGFR Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Stryker
Company Location: KALAMAZOO MI 49002
Company CEO: Kevin A. Lobo
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eptotermin alfa

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Other|Tibial Fractures

Phase 3: Pain Unspecified

Phase 2: Cleft Palate|Cleft Lip|Femoral Neck Fractures|Femoral Fractures

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BMP7

N/A

Terminated

Femur Head Necrosis

2017-05-01

2006-006727-39

P4

Completed

Unknown

2015-10-18

NCT00551941

P4

Terminated

Tibial Fractures

2012-07-09

The use of BMP for alveolar reconstruction

P2

Terminated

Cleft Lip|Cleft Palate

2010-11-01

Recent News Events

Date

Type

Title

05/15/2024

PubMed

 Porcine nasal septum cartilage-derived decellularized matrix promotes chondrogenic differentiation of human umbilical mesenchymal stem cells without exogenous growth factors.

05/13/2024

PubMed

 Novel cardiac extracellular matrix biomarkers in STEMI: Associations with ischemic injury and long-term mortality.

05/13/2024

PubMed

 The lack of EphB3 receptor prevents bone loss in mouse models of osteoporosis.

09/07/2021

News Article

 Bone Morphogenetic Protein Market Size Estimated to Reach $3,700 Million by 2026

08/03/2021

News Article

 Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

06/01/2020

News Article

 Orthopedic Joint Replacement Market to Gain Traction; Rising Prevalence of Bone Diseases to Boost Growth, states Fortune Business Insights™

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions